Measurement of surface protein antigens, PorA and PorB, in Bexsero vaccine using quantitative mass spectrometry. Issue 6 (5th February 2020)

• Record Type: Journal Article
• Authors: Whiting, Gail; Vipond, Caroline; Facchetti, Alessandra; Chan, Hannah; Wheeler, Jun X.
• Is Part Of: Vaccine. Volume 38:Issue 6(2020)
• Page Start: 1431
• Page End: 1435
• Publication Date: 2020-02-05
• Subjects: Bexsero vaccine -- Neisseria meningitis serogroup B -- MenB -- OMV -- Isotope dilution mass spectrometry; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.11.082
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Bexsero is a multivalent vaccine containing outer membrane vesicles (OMV) derived from Neisseria meningitidis group B strain NZ98/254 and three recombinant meningococcal proteins, Neisserial adhesin A, Heparin binding antigen and factor H binding protein. OMV production relies on the growth of large-scale cultures of N. meningitidis under controlled conditions. Changes to environmental factors, such as temperature, pH, nutrient availability and trace elements, can impact the growth rate of the meningococcus. Furthermore outer membrane expression levels vary in response to the environmental milieu, thus any changes in environmental conditions can result in changes in OMV protein content. This makes consistent production of OMVs challenging and the ability to measure the protein content of the final product is desirable to ensure product quality. The aim of this work was to develop a mass spectrometry (MS) method for measuring the porin proteins and to evaluate this approach for assessing the batch consistency of Bexsero vaccine. Using isotope dilution MS, we measured the PorA and PorB content in 75 lots of Bexsero vaccine. PorA ranged from 4.0 to 5.95 μg/dose with an average of 4.8 μg/dose. PorB ranged from 5.4 to 8.7 μg/dose with an average of 6.5 μg/dose. This is the first description of the quantitative characterisation of adjuvanted Bexsero vaccine drug product at the final stage of the production process, once the aluminium adjuvanted vaccine has been packaged into syringes, to assess manufacturing consistency. The significance of our findings to quality control in the future is discussed.